Pablo Corral on Lipid-Lowering Therapy and Cognition: Evidence vs Myth
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared on LinkedIn:
”Lipid-Lowering Therapy and Cognition: Evidence vs Myth
1. Elevated LDL-C remains the leading modifiable risk factor for cardiovascular disease and a major contributor to global mortality.
2. Concerns about cognitive adverse effects of lipid-lowering therapies (LLTs), particularly statins, are largely driven by early case reports rather than robust clinical evidence.
3. Observational studies and randomized trials consistently show no significant association between statin use and cognitive decline, with some data suggesting potential protective effects against dementia.
4. Major randomized trials (HPS, PROSPER, HOPE-3) found no difference in cognitive outcomes between statin-treated and placebo groups.
5. PCSK9 inhibitors (evolocumab, alirocumab) demonstrate neurocognitive safety, even with very low LDL-C levels and long-term exposure.
6. Ezetimibe and bempedoic acid show neutral neurocognitive profiles, with emerging signals of possible neuroprotective effects.
Current data support a clear conclusion:
- Lowering LDL-C improves cardiovascular outcomes without meaningful cognitive harm.
- The real knowledge gap is not safety, but understanding whether lipid-lowering therapies might also confer long-term neuroprotection.
Take-home message:
Fear of cognitive decline should not justify therapeutic inertia.
The price of untreated LDL-C is cardiovascular disease—not cognitive impairment.”
Read the full article here.
Article: Lipid-Lowering Therapies and Cognition in Older Adults: A Narrative Review and Clinical Considerations
Authors: Raiza Rossi, Armin Nouri, Zafer Akman, Shefa Arya Nezhad, Abdulla A. Damluji, Michael G. Nanna
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke